Interaksi Obat Antara Klopidogrel dan Proton Pump Inhibitor (PPI)
Penulis
Ni Made Amelia Ratnata DewiDOI:
10.29303/sjp.v1i1.12Diterbitkan:
2020-04-30Terbitan:
Vol 1 No 1 (2020): AprilKata Kunci:
Keywords, Interaksi obat, klopidogrel, proton pump inhibitorArticles
##submission.downloads##
Cara Mengutip
Abstrak
Abstrak: Pemberian Proton Pump Inhibitor (PPI) dapat menurunkan terjadinya kejadian perdarahan gastrointestinal berulang pada pasien yang mendapatkan dual therapy antiplatelet yaitu klopidogrel dan aspirin. Klopidogrel diaktivasi melalui proses metabolisme oleh enzim CYP2C19 sedangkan obat golongan PPI dimetabolisme dan menghambat enzim CYP2C19. Studi farmakodinamik menunjukkan adanya efek PPI terutama omeprazole terhadap metabolisme klopidogrel yang dapat mengakibatkan penurunan efek dari inhibisi platelet. Beberapa studi klinik mendapatkan bahwa tidak terdapat kejadian yang dapat menyebabkan permasalahan pada jantung (cardiovascular event) jika kedua obat diberikan secara bersamaan. Kemaknaan klinis dari interaksi obat dari klopidogrel dan PPI belum diketahui secara jelas sehingga untuk keamanan direkomendasikan untuk membatasi penggunaan PPI terutama omeprazole. Pilihan lain adalah dengan mengganti PPI dengan H2 blocker ataupun menggunakan golongan PPI yang tidak banyak dimetabolisme oleh enzim CYP2C19 seperti pantoprazole.Referensi
Barragan, P., Bouvier, J.-L., Roquebert, P.-O., Macaluso, G., Commeau, P., Comet, B., Lafont, A., Camoin, L., Walter, U., & Eigenthaler, M. (2003). Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheterization and Cardiovascular Interventions, 59(3), 295–302. https://doi.org/10.1002/ccd.10497
Bhatt, D. L., Cryer, B. L., Contant, C. F., Cohen, M., Lanas, A., Schnitzer, T. J., Shook, T. L., Lapuerta, P., Goldsmith, M. A., Laine, L., Scirica, B. M., Murphy, S. A., & Cannon, C. P. (2010). Clopidogrel with or without Omeprazole in Coronary Artery Disease. New England Journal of Medicine, 363(20), 1909–1917. https://doi.org/10.1056/NEJMoa1007964
Cuisset, T., Frere, C., Quilici, J., Poyet, R., Gaborit, B., Bali, L., Brissy, O., Morange, P.-E., Alessi, M.-C., & Bonnet, J.-L. (2009). Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose. Journal of the American College of Cardiology, 54(13), 1149–1153.
https://doi.org/10.1016/j.jacc.2009.05.050
Drug Information Handbook: Vol. 22th Ed. (2013). Wolters Kluwer Clinical Drug Information, Inc.
Farid, N. A., Kurihara, A., & Wrighton, S. A. (2010). Metabolism and Disposition of the Thienopyridine Antiplatelet Drugs Ticlopidine, Clopidogrel, and Prasugrel in Humans. The Journal of Clinical Pharmacology, 50(2), 126–142. https://doi.org/10.1177/0091270009343005
Ferreiro, J. L., Ueno, M., Tomasello, S. D., Tello-Montoliu, A., Capodanno, D., Seecheran, N., Pham, J. P., Kodali, M., Darlington, A., Desai, B., Charlton, R. K., Bass, T. A., & Angiolillo, D. J. (2011). IMPACT OF CONCOMITANT AND STAGGERED PANTOPRAZOLE INTAKE ON PHARMACODYNAMIC EFFECTS INDUCED BY CLOPIDOGREL. Journal of the American College of Cardiology, 57(14), E1907. https://doi.org/10.1016/S0735-1097(11)61907-4
Gilard, M., Arnaud, B., Cornily, J.-C., Le Gal, G., Lacut, K., Le Calvez, G., Mansourati, J., Mottier, D., Abgrall, J.-F., & Boschat, J. (2008). Influence of Omeprazole on the Antiplatelet Action of Clopidogrel Associated With Aspirin. Journal of the American College of Cardiology, 51(3), 256–260. https://doi.org/10.1016/j.jacc.2007.06.064
Ho, P. M., Maddox, T. M., Wang, L., Fihn, S. D., Jesse, R. L., Peterson, E. D., & Rumsfeld, J. S. (n.d.). Risk of Adverse Outcomes Associated With Concomitant Use of Clopidogrel and Proton Pump Inhibitors Following Acute Coronary Syndrome. 8.
Ieiri, I., Kimura, M., Irie, S., Urae, A., Otsubo, K., & Ishizaki, T. (2005). Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP2C19 genotypic status: Pharmacogenetics and Genomics, 15(12), 851–859. https://doi.org/10.1097/01213011-200512000-00003
Lai, K. C., Lam, S. K., Chu, K. M., Wong, B. C. Y., Hui, W. M., Hu, W. H. C., Lau, G. K. K., Wong, W. M., Yuen, M. F., Chan, A. O. O., Lai, C. L., & Wong, J. (2002). Lansoprazole for the Prevention of Recurrences of Ulcer Complications from Long-Term Low-Dose Aspirin Use. New England Journal of Medicine, 346(26), 2033–2038. https://doi.org/10.1056/NEJMoa012877
Ogawa, R., & Echizen, H. (2010). Drug-Drug Interaction Profiles of Proton Pump Inhibitors: Clinical Pharmacokinetics, 49(8), 509–533. https://doi.org/10.2165/11531320-000000000-00000
Peters, R. J. G., Mehta, S. R., Fox, K. A. A., Zhao, F., Lewis, B. S., Kopecky, S. L., Diaz, R., Commerford, P. J., Valentin, V., & Yusuf, S. (2003). Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes: Observations From the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study. Circulation, 108(14), 1682–1687. https://doi.org/10.1161/01.CIR.0000091201.39590.CB
Peters, R. J. G., Mehta, S., & Yusuf, S. (2007). Acute coronary syndromes without ST segment elevation. BMJ, 334(7606), 1265–1269. https://doi.org/10.1136/bmj.39220.618646.AE
Ray, W. A., Smalley, W. E., Hall, K., & Daugherty, J. R. (2011). Outcomes with Concurrent Use of Clopidogrel and Proton-Pump Inhibitors: A Cohort Study. 16.
Sibbing, D., Morath, T., Stegherr, J., Braun, S., Vogt, W., Hadamitzky, M., Schömig, A., Kastrati, A., & Beckerath, N. von. (2009). Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thrombosis and Haemostasis, 101(04), 714–719. https://doi.org/10.1160/TH08-12-0808
Tantry, U. S., Kereiakes, D. J., & Gurbel, P. A. (2011). Clopidogrel and Proton Pump Inhibitors. JACC: Cardiovascular Interventions, 4(4), 365–380. https://doi.org/10.1016/j.jcin.2010.12.009
Bhatt, D. L., Scheiman, J., Abraham, N. S., Antman, E. M., Chan, F. K. L., Furberg, C. D., Johnson, D. A., Mahaffey, K. W., & Quigley, E. M. (2008). ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation, 118(18), 1894–1909. https://doi.org/10.1161/CIRCULATIONAHA.108.191087
.
Lisensi
Authors who publish with Sasambo Journal of Pharmacy (SJP), agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Lisensi Creative Commons Atribusi 4.0 Internasional. This license allows authors to use all articles, data sets, graphics and appendices in data mining applications, search engines, web sites, blogs, and other platforms by providing an appropriate reference. The journal allows the author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Sasambo Journal of Pharmacy
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
